Thermo Fisher Scientific TMO
$694.76 +$17.82 (+2.63%)
Market closed · Nov 6, 8:10 pm ET · Last extended-hours $694.76 0.00%
Open$669.20
Prev close$676.94
Day range$661.60 – $697.78
Volume2.09M
Market cap$257.42B
P/E (TTM)36.6
Dividend yield0.26%
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Institutional ownership92.0%-0.79 pts vs. prior quarter
Institutions holding3,234+97 vs. prior quarter
Insider trades (recent)22 buys / 28 sellsNet selling
Short interest1.32% of floatDays to cover 2.2 · as of 15 Oct 2026
Short-sale volume share13.4%5-day average of daily volume
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$118.05M (8 inflow days, 12 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 27.0% of shares outstanding.
Largest holders
By investor type
Reported short interest has held roughly steady near 1.32% of float over the last 6 biweekly reports (31 Jul 2026 to 15 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| FMR | Mutual Fund | 2026/Q3 | +3,236,781 | 3.3% |
| Dodge & Cox | Mutual Fund | 2026/Q3 | +3,029,037 | 0.8% |
| J.P. Morgan Asset Management, Inc. | Mutual Fund | 2026/Q3 | +1,235,830 | 1.0% |
| SG Americas Securities, LLC | Private Company | 2026/Q3 | +803,535 | 0.3% |
| Brewin Dolphin Wealth Management Limited | Mutual Fund | 2026/Q3 | +637,943 | 0.2% |
| BlackRock | Mutual Fund | 2026/Q3 | +492,440 | 8.4% |
| Putnam LLC | Mutual Fund | 2026/Q3 | +458,159 | 1.2% |
| Glenview Capital Management, LLC | Hedge Fund | 2026/Q3 | +376,715 | 0.2% |
| Arrowstreet Capital, Limited Partnership | Mutual Fund | 2026/Q3 | +373,025 | 0.3% |
| D. E. Shaw & Co., L.P. | Hedge Fund | 2026/Q3 | +338,789 | 0.2% |
| Qube Research & Technologies Ltd | Mutual Fund | 2026/Q3 | +303,806 | 0.1% |
| JPMorgan Chase & Co. | Public Company | 2026/Q3 | +299,775 | 1.3% |
| Blue Sparrow, Llc | Mutual Fund | 2026/Q3 | +271,300 | 0.1% |
| Viking Global Investors LP | Hedge Fund | 2026/Q3 | +269,390 | 0.5% |
| EdgePoint Investment Group Inc. | Hedge Fund | 2026/Q3 | +260,653 | 0.6% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 25 Sep 2026 | Scott Sperling | Lead Independent Director | Other Derivative Acquisition | +62 | – | 17,738 |
| 25 Sep 2026 | Jennifer Johnson | Independent Director | Other Derivative Acquisition | +46 | – | 769 |
| 25 Sep 2026 | Karen Lynch | Independent Director | Other Derivative Acquisition | +46 | – | 399 |
| 25 Sep 2026 | Dion Weisler | Independent Director | Other Derivative Acquisition | +55 | – | 2,847 |
| 25 Sep 2026 | R. Keith | Independent Director | Other Derivative Acquisition | +46 | – | 1,378 |
| 30 Aug 2026 | Gianluca Pettiti | President, COO & President of Products and Technologies | Automatic Disposition | -400 | $614.38 | 23,216 |
| 30 Aug 2026 | Gianluca Pettiti | President, COO & President of Products and Technologies | Derivative Exercise and Sale | -3,733 | $614.38 | 23,216 |
| 27 Aug 2026 | Marc Casper | Chairperson & CEO | Sale to Issuer | -1,256 | $622.18 | 126,047 |
| 27 Aug 2026 | Thomas Shropshire | Senior VP and General Counsel | Sale to Issuer | -49 | $622.18 | 6,009 |
| 27 Aug 2026 | Lisa Britt | Chief Human Resources Officer & Senior VP | Sale to Issuer | -393 | $622.18 | 12,939 |
| 27 Aug 2026 | Gianluca Pettiti | President, COO & President of Products and Technologies | Sale to Issuer | -1,034 | $622.18 | 23,216 |
| 27 Aug 2026 | Michael Shafer | Executive VP & President of Biopharma Services | Sale to Issuer | -790 | $622.18 | 17,576 |
| 27 Aug 2026 | Joseph Holmes | Vice President | Sale to Issuer | -49 | $622.18 | 2,470 |
| 27 Aug 2026 | James Meyer | Senior Vice President | Sale to Issuer | -270 | $622.18 | 5,618 |
| 23 Aug 2026 | Marc Casper | Chairperson & CEO | Derivative Exercise and Sale | -275 | $628.74 | 127,303 |
| 21 Aug 2026 | James Meyer | Senior Vice President | Sale to Issuer | -30 | $629.27 | 5,888 |
| 20 Aug 2026 | Marc Casper | Chairperson & CEO | Intent to Sell (Form 144) | -10,000 | $626.91 | – |
| 20 Aug 2026 | Marc Casper | Chairperson & CEO | Derivative Exercise and Sale | -20,000 | $633.99 | 127,303 |
| 19 Aug 2026 | Marc Casper | Chairperson & CEO | Intent to Sell (Form 144) | -10,000 | $629.27 | – |
| 18 Aug 2026 | Lisa Britt | Chief Human Resources Officer & Senior VP | Derivative Exercise and Sale | -11,440 | $613.12 | 13,332 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 4,887,534 | 1.3% | 2.2 |
| 30 Sep 2026 | 5,408,135 | 1.5% | 2.1 |
| 15 Sep 2026 | 5,019,933 | 1.4% | 2.7 |
| 31 Aug 2026 | 5,690,588 | 1.5% | 3.4 |
| 14 Aug 2026 | 4,744,180 | 1.3% | 2.9 |
| 31 Jul 2026 | 4,985,877 | 1.3% | 1.9 |
No comments yet — be the first to weigh in on TMO.
Sign in to join the discussion.